Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

188.12
-12.7500-6.35%
Post-market: 188.600.4800+0.26%19:58 EDT
Volume:4.86M
Turnover:903.35M
Market Cap:40.32B
PE:-21.09
High:199.64
Open:198.51
Low:180.49
Close:200.87
52wk High:224.31
52wk Low:46.16
Shares:214.34M
Float Shares:185.00M
Volume Ratio:3.07
T/O Rate:2.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:15.47
PE(LYR):-31.62

Loading ...

Revolution Medicines is Maintained at Outperform by Mizuho

Dow Jones
·
Jul 06

Revolution Medicines Inc : Mizuho Raises Target Price to $215 from $185

THOMSON REUTERS
·
Jul 06

Wedbush Raises Price Target on Revolution Medicines to $181 From $165, Keeps Outperform Rating

MT Newswires Live
·
Jul 06

Will Strong Early Zoldonrasib Pancreatic Data Change Revolution Medicines' (RVMD) RAS-Focused Narrative?

Simply Wall St.
·
Jul 06

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Johnson & Johnson (JNJ)

TIPRANKS
·
Jul 04

Revolution Medicines is Maintained at Outperform by Wedbush

Dow Jones
·
Jul 03

Revolution Medicines: Strong Zoldonrasib Data in G12D Pancreatic Cancer Support Buy Rating and Unchanged $263 Price Target

TIPRANKS
·
Jul 03

Revolution Medicines Advances Zoldonrasib to Phase 3 After Strong Pancreatic Cancer Trial Results

Dow Jones
·
Jul 02

Revolution Medicines Reports Release Available on Zoldonrasib Combination Data in RAS G12D Metastatic Pancreatic Cancer

Reuters
·
Jul 02

Revolution Medicines Director Sushil Patel Disposes of 5,580 Common Shares Worth $1.04 Million

Reuters
·
Jul 02

Revolution Medicines is Maintained at Buy by Truist Securities

Dow Jones
·
Jun 30

Revolution Medicines price target raised to $210 from $179 at Truist

TIPRANKS
·
Jun 30

Movement Alert|Revolution Medicines Rises 5.07% in Regular Trading, ESMO GI Data Exceeds Expectations with Strong ORR Results

Market Focus
·
Jun 30

Revolution Medicines is Maintained at Buy by Needham

Dow Jones
·
Jun 29

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Apogee Therapeutics (APGE)

TIPRANKS
·
Jun 29

U.S. Research Roundup-3m Co, Nike, Primoris Services

Reuters
·
Jun 29

Revolution Medicines CFO Jack Anders Reports $3.35 Million Common Stock Disposal

Reuters
·
Jun 27

This Biotech ETF Has Almost Doubled in 13 Months. Money is Flowing In.

Dow Jones
·
Jun 27

Revolution Medicines Faces 'Uphill Battle' in Potential Patent Claim Against Erasca, RBC Says

MT Newswires Live
·
Jun 26

Movement Alert|Revolution Medicines Rises 5.91% in Regular Trading, Rasolute 305 Phase 3 Trial Dosing Initiated and UBS Highlights 40% Revenue Upside

Market Focus
·
Jun 25